Приказ основних података о документу

dc.creatorMedenica, Mirjana
dc.creatorIvanović, D.
dc.creatorMagković, M.
dc.creatorJančić, Biljana
dc.creatorMalenović, Anđelija
dc.date.accessioned2019-09-02T11:10:46Z
dc.date.available2019-09-02T11:10:46Z
dc.date.issued2007
dc.identifier.issn0731-7085
dc.identifier.urihttps://farfar.pharmacy.bg.ac.rs/handle/123456789/968
dc.description.abstractPerindopril tert-butylamine is a new member of angiotensin-converting enzyme inhibitors group used in the treatment of hypertension and heart failure. In this paper, the evaluation of reversed-phase high-performance liquid chromatographic method (RP-HPLC) for the determination of impurities level of perindopril tert-butylamine in tablets was done. The chromatograms were recorded using a Hewlett Packard 1100 chromatographic system with DAD detector. Separations were performed on a YMC-Pack C8 column (250 mm x 4.6 mm; 5 mu m particle size) at 50 degrees C column temperature. Mobile phase was a mixture of acetonitrile-potassium phosphate buffer (0.05 M) (37:63, v/v) (pH 2.5). pH of the mobile phase was adjusted with ortophosphoric acid. Mixture of acetonitrile-water (40:60, v/v) was used as a solvent. Injection volume was 50 mu l, flow rate 1.7 ml min(-1) and UV-detection was performed at 215 nm. The developed method subjected to method validation and parameters in terms of selectivity, linearity, precision, accuracy, limit of detection, limit of quantitation and robustness were defined. The validated method is suitable for the simultaneous determination of perindopril tert-butylamine as well as its impurities in pharmaceuticals.en
dc.publisherElsevier Science BV, Amsterdam
dc.relationinfo:eu-repo/grantAgreement/MESTD/MPN2006-2010/142077/RS//
dc.rightsrestrictedAccess
dc.sourceJournal of Pharmaceutical and Biomedical Analysis
dc.subjectperindopril tert-butylamineen
dc.subjectperindoprilaten
dc.subjectimpuritiesen
dc.subjecthigh-performance liquid chromatographyen
dc.subjectvalidationen
dc.titleEvaluation of impurities level of perindopril tert-butylamine in tabletsen
dc.typearticle
dc.rights.licenseARR
dcterms.abstractЈанчић, Биљана; Маленовић, Aнђелија; Магковић, М.; Ивановић, Д.; Меденица, Мирјана;
dc.citation.volume44
dc.citation.issue5
dc.citation.spage1087
dc.citation.epage1094
dc.citation.other44(5): 1087-1094
dc.citation.rankM21
dc.identifier.wos000249469000009
dc.identifier.doi10.1016/j.jpba.2007.05.008
dc.identifier.pmid17590561
dc.identifier.scopus2-s2.0-34547757006
dc.type.versionpublishedVersion


Документи

Thumbnail

Овај документ се појављује у следећим колекцијама

Приказ основних података о документу